Biotek-snakken — August 2024
-
Genovis Q2 2024: Focusing fully on the enzyme business
"Consequently, our updated fair value range amounts to SEK24-102, with a base case of SEK52."
-
Vedr.; Infant Bacterial Therapeutics:
"The final patient participating in “The Connection Study” is expected to leave the study during July 2024. The results from the study are anticipated during Q3 2024" (April 4, 2024).
Dvs. at resultatet forventes senest den kommende måned.
-
Weekly Biotech Buzz: AADI Trims R&D Jobs, JNJ Loosens Purse Strings, FDA Snubs REGN's Myeloma Drug https://proinvestor.com/investornyt/1204790/weekly-biotech-buzz-aadi-trims-rampd-jobs-jnj-loosens-purse-strings-fda-snubs-regns-myeloma-drug
-
Infant Bacterial Therapeutics AB (publ), Interim report January 1 – June 30, 2024 https://storage.mfn.se/e4463f81-0644-4c84-87fa-25f773e47ef8/ibt-q2-2024-eng.pdf
-
This spring, the regulatory work began to prepare IBT's drug application for IBP-9414. The work has intensified, and more sections are ready. As soon as we have received results from “The Connection Study” IBT intends to contact the FDA and discuss how they want us to submit our data with the objective of reaching the market as soon as possible
og stort tillykke med den fantastiske opbakning til dette meget informative site med masser af god faglig input og debat 
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind